Mutations leading to constitutive active gp130/JAK1/STAT3 pathway

Cytokine and Growth Factor Reviews

Volumn 26, Issue 5, 2015, Pages 499-506

  Pilati, Camilla ^a,b,c,d   Zucman Rossi, Jessica ^a,b,c,d  

^a INSERM   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c UNIVERSITÉ PARIS 13   (France)

^d HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

FRK; GNAS; Gp130; Inflammatory hepatocellular adenomas; JAK1; STAT3

Indexed keywords

4 AMINO 7 TERT BUTYL 5 (4 CHLOROPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; ANTINEOPLASTIC AGENT; CARDIOTROPHIN 1; CILIARY NEUROTROPHIC FACTOR RECEPTOR; CURCUMIN; DASATINIB; GLYCOPROTEIN GP 130; HEPATOCYTE NUCLEAR FACTOR 1ALPHA; INTERLEUKIN 11; INTERLEUKIN 27; INTERLEUKIN 3; INTERLEUKIN 6; JANUS KINASE 1; JANUS KINASE 2; JANUS KINASE 3; LEUKEMIA INHIBITORY FACTOR; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; NUCLEAR RECEPTOR COACTIVATOR 2; ONCOSTATIN M; PROTEIN SH2; RUXOLITINIB; SRCL 1; SRCL 5; STAT3 PROTEIN; UNCLASSIFIED DRUG; FRK PROTEIN, HUMAN; IL6ST PROTEIN, HUMAN; JAK1 PROTEIN, HUMAN; PROTEIN TYROSINE KINASE; STAT3 PROTEIN, HUMAN; TUMOR PROTEIN;

CANCER GROWTH; CHRONIC MYELOID LEUKEMIA; CONFORMATIONAL TRANSITION; FRK GENE; GENE CONTROL; GENE IDENTIFICATION; GENE LOCUS; GENE MUTATION; GNAS GENE; GP130 GENE; HUMAN; JAK1 GENE; LIVER ADENOMA; MALIGNANT TRANSFORMATION; MYELOPROLIFERATIVE DISORDER; NONHUMAN; PRIORITY JOURNAL; PROTEIN MOTIF; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; SHORT SURVEY; SIGNAL TRANSDUCTION; STAT3 GENE; UPREGULATION; ANIMAL; GENETICS; IMMUNOLOGY; MUTATION; NEOPLASM;

ANIMALS; CYTOKINE RECEPTOR GP130; HUMANS; JANUS KINASE 1; MUTATION; NEOPLASM PROTEINS; NEOPLASMS; PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

EID: 84941882702     PISSN: 13596101     EISSN: 18790305     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2015.07.010     Document Type: Short Survey

References (95)

1. Turkson J., Jove R. STAT proteins: novel molecular targets for cancer drug discovery. Oncogene 2000, 19:6613-6626.
2. Bromberg J. Stat proteins and oncogenesis. J. Clin. Invest. 2002, 109:1139-1142.
3. Boulanger M.J., Chow D.C., Brevnova E.E., Garcia K.C. Hexameric structure and assembly of the interleukin-6/IL-6 alpha-receptor/gp130 complex. Science 2003, 300:2101-2104.
4. Ward L.D., Howlett G.J., Discolo G., Yasukawa K., Hammacher A., Moritz R.L., et al. High affinity interleukin-6 receptor is a hexameric complex consisting of two molecules each of interleukin-6, interleukin-6 receptor, and gp-130. J. Biol. Chem. 1994, 269:23286-23289.
5. Cherqui D., Rahmouni A., Charlotte F., Boulahdour H., Metreau J.M., Meignan M., et al. Management of focal nodular hyperplasia and hepatocellular adenoma in young women: a series of 41 patients with clinical, radiological, and pathological correlations. Hepatology 1995, 22:1674-1681.
6. Nault J.C., Bioulac-Sage P., Zucman-Rossi J. Hepatocellular benign tumors-from molecular classification to personalized clinical care. Gastroenterology 2013, 144:888-902.
7. Zucman-Rossi J., Jeannot E., Nhieu J.T., Scoazec J.Y., Guettier C., Rebouissou S., et al. Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC. Hepatology 2006, 43:515-524.
8. Bacq Y., Jacquemin E., Balabaud C., Jeannot E., Scotto B., Branchereau S., et al. Familial liver adenomatosis associated with hepatocyte nuclear factor 1alpha inactivation. Gastroenterology 2003, 125:1470-1475.
9. Bluteau O., Jeannot E., Bioulac-Sage P., Marques J.M., Blanc J.F., Bui H., et al. Bi-allelic inactivation of TCF1 in hepatic adenomas. Nat. Genet. 2002, 32:312-315.
10. Chen Y.W., Jeng Y.M., Yeh S.H., Chen P.J. P53 gene and Wnt signaling in benign neoplasms: beta-catenin mutations in hepatic adenoma but not in focal nodular hyperplasia. Hepatology 2002, 36:927-935.
11. Pilati C., Letouze E., Nault J.C., Imbeaud S., Boulai A., Calderaro J., et al. Genomic profiling of hepatocellular adenomas reveals recurrent FRK-activating mutations and the mechanisms of malignant transformation. Cancer Cell 2014, 25:428-441.
12. Bioulac-Sage P., Rebouissou S., Thomas C., Blanc J.F., Saric J., Sa Cunha A., et al. Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry. Hepatology 2007, 46:740-748.
13. Rebouissou S., Amessou M., Couchy G., Poussin K., Imbeaud S., Pilati C., et al. Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours. Nature 2009, 457:200-204.
14. Poussin K., Pilati C., Couchy G., Calderaro J., Bioulac-Sage P., Bacq Y., et al. Biochemical and functional analyses of gp130 mutants unveil JAK1 as a novel therapeutic target in human inflammatory hepatocellular adenoma. Oncoimmunology 2013, 2:e27090.
15. Pilati C., Amessou M., Bihl M.P., Balabaud C., Nhieu J.T., Paradis V., et al. Somatic mutations activating STAT3 in human inflammatory hepatocellular adenomas. J. Exp. Med. 2011, 208:1359-1366.
16. Nault J.C., Fabre M., Couchy G., Pilati C., Jeannot E., Tran Van Nhieu J., et al. GNAS-activating mutations define a rare subgroup of inflammatory liver tumors characterized by STAT3 activation. J. Hepatol. 2012, 56:184-191.
17. Boulton T.G., Stahl N., Yancopoulos G.D. Ciliary neurotrophic factor/leukemia inhibitory factor/interleukin 6/oncostatin M family of cytokines induces tyrosine phosphorylation of a common set of proteins overlapping those induced by other cytokines and growth factors. J. Biol. Chem. 1994, 269:11648-11655.
18. Boulanger M.J., Bankovich A.J., Kortemme T., Baker D., Garcia K.C. Convergent mechanisms for recognition of divergent cytokines by the shared signaling receptor gp130. Mol. Cell 2003, 12:577-589.
19. Skiniotis G., Lupardus P.J., Martick M., Walz T., Garcia K.C. Structural organization of a full-length gp130/LIF-R cytokine receptor transmembrane complex. Mol. Cell 2008, 31:737-748.
20. Schutt A., Zacharias M., Schneider N., Horn S., Grotzinger J., Rose-John S., et al. gp130 activation is regulated by D2-D3 interdomain connectivity. Biochem. J. 2013, 450:487-496.
21. Schmidt-Arras D., Muller M., Stevanovic M., Horn S., Schutt A., Bergmann J., et al. Oncogenic deletion mutants of gp130 signal from intracellular compartments. J. Cell Sci. 2014, 127:341-353.
22. Taniguchi K., Wu L.W., Grivennikov S.I., de Jong P.R., Lian I., Yu F.X., et al. A gp130-Src-YAP module links inflammation to epithelial regeneration. Nature 2015, 519:57-62.
23. Lee J., Wang Z., Luoh S.M., Wood W.I., Scadden D.T. Cloning of FRK, a novel human intracellular SRC-like tyrosine kinase-encoding gene. Gene 1994, 138:247-251.
24. Frame M.C. Src in cancer: deregulation and consequences for cell behaviour. Biochim. Biophys. Acta 2002, 1602:114-130.
25. Levy J.B., Iba H., Hanafusa H. Activation of the transforming potential of p60c-src by a single amino acid change. Proc. Natl. Acad. Sci. U.S.A 1986, 83:4228-4232.
26. Shuai K., Horvath C.M., Huang L.H., Qureshi S.A., Cowburn D., Darnell J.E. Interferon activation of the transcription factor Stat91 involves dimerization through SH2-phosphotyrosyl peptide interactions. Cell 1994, 76:821-828.
27. Wen Z., Zhong Z., Darnell J.E. Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation. Cell 1995, 82:241-250.
28. Bromberg J.F., Wrzeszczynska M.H., Devgan G., Zhao Y., Pestell R.G., Albanese C., et al. Stat3 as an oncogene. Cell 1999, 98:295-303.
29. Scarzello A.J., Romero-Weaver A.L., Maher S.G., Veenstra T.D., Zhou M., Qin A., et al. A Mutation in the SH2 domain of STAT2 prolongs tyrosine phosphorylation of STAT1 and promotes type I IFN-induced apoptosis. Mol. Biol. Cell 2007, 18:2455-2462.
30. Constantinescu S.N., Girardot M., Pecquet C. Mining for JAK-STAT mutations in cancer. Trends Biochem. Sci. 2008, 33:122-131.
31. Chen X., Bhandari R., Vinkemeier U., Van Den Akker F., Darnell J.E., Kuriyan J. A reinterpretation of the dimerization interface of the N-terminal domains of STATs. Protein Sci.: Publ. Protein Soc. 2003, 12:361-365.
32. Domoszlai T., Martincuks A., Fahrenkamp D., Schmitz-Van de Leur H., Kuster A., Muller-Newen G. Consequences of the disease-related L78R mutation for dimerization and activity of STAT3. J. Cell Sci. 2014, 127:1899-1910.
33. Zhang T., Kee W.H., Seow K.T., Fung W., Cao X. The coiled-coil domain of Stat3 is essential for its SH2 domain-mediated receptor binding and subsequent activation induced by epidermal growth factor and interleukin-6. Mol. Cell. Biol. 2000, 20:7132-7139.
34. Kalfa N., Lumbroso S., Boulle N., Guiter J., Soustelle L., Costa P., et al. Activating mutations of Gsalpha in kidney cancer. J. Urol. 2006, 176:891-895.
35. Kan Z., Jaiswal B.S., Stinson J., Janakiraman V., Bhatt D., Stern H.M., et al. Diverse somatic mutation patterns and pathway alterations in human cancers. Nature 2010, 466:869-873.
36. Mantovani G., Bondioni S., Lania A.G., Corbetta S., de Sanctis L., Cappa M., et al. Parental origin of Gsalpha mutations in the McCune-Albright syndrome and in isolated endocrine tumors. J. Clin. Endocrinol. Metab. 2004, 89:3007-3009.
37. Palos-Paz F., Perez-Guerra O., Cameselle-Teijeiro J., Rueda-Chimeno C., Barreiro-Morandeira F., Lado-Abeal J., et al. Prevalence of mutations in TSHR, GNAS PRKAR1A and RAS genes in a large series of toxic thyroid adenomas from Galicia, an iodine-deficient area in NW Spain. Eur. J. Endocrinol. 2008, 159:623-631.
38. Sjoblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., et al. The consensus coding sequences of human breast and colorectal cancers. Science 2006, 314:268-274.
39. Weinstein L.S., Liu J., Sakamoto A., Xie T., Chen M. Mini review: GNAS: normal and abnormal functions. Endocrinology 2004, 145:5459-5464.
40. Muca C., Vallar L. Expression of mutationally activated G alpha s stimulates growth and differentiation of thyroid FRTL5 cells. Oncogene 1994, 9:3647-3653.
41. Weinstein L.S., Shenker A., Gejman P.V., Merino M.J., Friedman E., Spiegel A.M. Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. N. Engl. J. Med. 1991, 325:1688-1695.
42. Zhang J., Ding L., Holmfeldt L., Wu G., Heatley S.L., Payne-Turner D., et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature 2012, 481:157-163.
43. Harrison C., Kiladjian J.J., Al-Ali H.K., Gisslinger H., Waltzman R., Stalbovskaya V., et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N. Engl. J. Med. 2012, 366:787-798.
44. Quintas-Cardama A., Vaddi K., Liu P., Manshouri T., Li J., Scherle P.A., et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood 2010, 115:3109-3117.
45. Miyamoto N., Sugita K., Goi K., Inukai T., Lijima K., Tezuka T., et al. The JAK2 inhibitor AG490 predominantly abrogates the growth of human B-precursor leukemic cells with 11q23 translocation or Philadelphia chromosome. Leukemia 2001, 15:1758-1768.
46. Milacic V., Banerjee S., Landis-Piwowar K.R., Sarkar F.H., Majumdar A.P., Dou Q.P. Curcumin inhibits the proteasome activity in human colon cancer cells in vitro and in vivo. Cancer Res. 2008, 68:7283-7292.
47. Edwards J. Src kinase inhibitors: an emerging therapeutic treatment option for prostate cancer. Expert Opin. Invest. Drugs 2010, 19:605-614.
48. Kantarjian H., Shah N.P., Hochhaus A., Cortes J., Shah S., Ayala M., et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med. 2010, 362:2260-2270.
49. Fagard R., Metelev V., Souissi I., Baran-Marszak F. STAT3 inhibitors for cancer therapy: have all roads been explored?. Jak-Stat 2013, 2:e22882.
50. Rajala H.L., Porkka K., Maciejewski J.P., Loughran T.P., Mustjoki S. Uncovering the pathogenesis of large granular lymphocytic leukemia-novel STAT3 and STAT5b mutations. Ann. Med. 2014, 46:114-122.
51. Couronne L., Scourzic L., Pilati C., Della Valle V., Duffourd Y., Solary E., et al. STAT3 mutations identified in human hematologic neoplasms induce myeloid malignancies in a mouse bone marrow transplantation model. Haematologica 2013, 98:1748-1752.
52. Crescenzo R., Abate F., Lasorsa E., Tabbo F., Gaudiano M., Chiesa N., et al. Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma. Cancer Cell 2015, 27:516-532.
53. Stoot J.H., Coelen R.J., De Jong M.C., Dejong C.H. Malignant transformation of hepatocellular adenomas into hepatocellular carcinomas: a systematic review including more than 1600 adenoma cases. HPB (Oxford) 2010, 12:509-522.
54. Farges O., Ferreira N., Dokmak S., Belghiti J., Bedossa P., Paradis V. Changing trends in malignant transformation of hepatocellular adenoma. Gut 2011, 60:85-89.
55. Guichard C., Amaddeo G., Imbeaud S., Ladeiro Y., Pelletier L., Maad I.B., et al. Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat. Genet. 2012, 44:694-698.
56. Lacronique V., Boureux A., Valle V.D., Poirel H., Quang C.T., Mauchauffe M., et al. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science 1997, 278:1309-1312.
57. Peeters P., Raynaud S.D., Cools J., Wlodarska I., Grosgeorge J., Philip P., et al. Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia. Blood 1997, 90:2535-2540.
58. Baxter E.J., Scott L.M., Campbell P.J., East C., Fourouclas N., Swanton S., et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005, 365:1054-1061.
59. James C., Ugo V., Le Couedic J.P., Staerk J., Delhommeau F., Lacout C., et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005, 434:1144-1148.
60. Kralovics R., Passamonti F., Buser A.S., Teo S.S., Tiedt R., Passweg J.R., et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N. Engl. J. Med. 2005, 352:1779-1790.
61. Levine R.L., Wadleigh M., Cools J., Ebert B.L., Wernig G., Huntly B.J., et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005, 7:387-397.
62. Scott L.M., Tong W., Levine R.L., Scott M.A., Beer P.A., Stratton M.R., et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N. Engl. J. Med. 2007, 356:459-468.
63. Asnafi V., Le Noir S., Lhermitte L., Gardin C., Legrand F., Vallantin X., et al. JAK1 mutations are not frequent events in adult T-ALL: a GRAALL study. Br. J. Haematol. 2010, 148:178-179.
64. Flex E., Petrangeli V., Stella L., Chiaretti S., Hornakova T., Knoops L., et al. Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia. J. Exp. Med. 2008, 205:751-758.
65. Mullighan C.G., Zhang J., Harvey R.C., Collins-Underwood J.R., Schulman B.A., Phillips L.A., et al. JAKmutations in high-risk childhood acute lymphoblastic leukemia. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:9414-9418.
66. Xiang Z., Zhao Y., Mitaksov V., Fremont D.H., Kasai Y., Molitoris A., et al. Identification of somatic JAK1 mutations in patients with acute myeloid leukemia. Blood 2008, 111:4809-4812.
67. Elliott N.E., Cleveland S.M., Grann V., Janik J., Waldmann T.A., Dave U.P. FERM domain mutations induce gain of function in JAK3 in adult T-cell leukemia/lymphoma. Blood 2011, 118:3911-3921.
68. Koo G.C., Tan S.Y., Tang T., Poon S.L., Allen G.E., Tan L., et al. Janus kinase 3-activating mutations identified in natural killer/T-cell lymphoma. Cancer Discov. 2012, 2:591-597.
69. Kan Z., Zheng H., Liu X., Li S., Barber T.D., Gong Z., et al. Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma. Genome Res. 2013, 23:1422-1433.
70. Xie H.J., Bae H.J., Noh J.H., Eun J.W., Kim J.K., Jung K.H., et al. Mutational analysis of JAK1 gene in human hepatocellular carcinoma. Neoplasma 2009, 56:136-140.
71. Jeong E.G., Kim M.S., Nam H.K., Min C.K., Lee S., Chung Y.J., et al. Somatic mutations of JAK1 and JAK3 in acute leukemias and solid cancers. Clin. Cancer Res. 2008, 14:3716-3721. (An Official Journal of the American Association for Cancer Research).
72. Staerk J., Kallin A., Demoulin J.B., Vainchenker W., Constantinescu S.N. JAK1 and Tyk2 activation by the homologous polycythemia vera JAK2 V617F mutation: cross-talk with IGF1 receptor. J. Biol. Chem. 2005, 280:41893-41899.
73. Chen M., Cheng A., Candotti F., Zhou Y.J., Hymel A., Fasth A., et al. Complex effects of naturally occurring mutations in the JAK3 pseudokinase domain: evidence for interactions between the kinase and pseudokinase domains. Mol. Cell. Biol. 2000, 20:947-956.
74. Lindauer K., Loerting T., Liedl K.R., Kroemer R.T. Prediction of the structure of human Janus kinase 2 (JAK2) comprising the two carboxy-terminal domains reveals a mechanism for autoregulation. Protein Eng. 2001, 14:27-37.
75. Saharinen P., Silvennoinen O. The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction. J. Biol. Chem. 2002, 277:47954-47963.
76. Lupardus P.J., Ultsch M., Wallweber H., Bir Kohli P., Johnson A.R., Eigenbrot C. Structure of the pseudokinase-kinase domains from protein kinase TYK2 reveals a mechanism for Janus kinase (JAK) autoinhibition. Proc. Natl. Acad. Sci. U.S.A. 2014, 111:8025-8030.
77. Koskela H.L., Eldfors S., Ellonen P., van Adrichem A.J., Kuusanmaki H., Andersson E.I., et al. Somatic STAT3 mutations in large granular lymphocytic leukemia. N. Engl. J. Med. 2012, 366:1905-1913.
78. Fasan A., Kern W., Grossmann V., Haferlach C., Haferlach T., Schnittger S. STAT3 mutations are highly specific for large granular lymphocytic leukemia. Leukemia 2013, 27:1598-1600.
79. Jerez A., Clemente M.J., Makishima H., Koskela H., Leblanc F., Peng Ng K., et al. STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia. Blood 2012, 120:3048-3057.
80. Holland S.M., DeLeo F.R., Elloumi H.Z., Hsu A.P., Uzel G., Brodsky N., et al. STAT3 mutations in the hyper-IgE syndrome. N. Engl. J. Med. 2007, 357:1608-1619.
81. Minegishi Y., Saito M., Tsuchiya S., Tsuge I., Takada H., Hara T., et al. Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome. Nature 2007, 448:1058-1062.
82. Rajala H.L., Eldfors S., Kuusanmaki H., van Adrichem A.J., Olson T., Lagstrom S., et al. Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia. Blood 2013, 121:4541-4550.
83. Bolen J.B., Veillette A., Schwartz A.M., DeSeau V., Rosen N. Activation of pp60c-src protein kinase activity in human colon carcinoma. Proc. Natl. Acad. Sci. U.S.A. 1987, 84:2251-2255.
84. Egan C., Pang A., Durda D., Cheng H.C., Wang J.H., Fujita D.J. Activation of Src in human breast tumor cell lines: elevated levels of phosphotyrosine phosphatase activity that preferentially recognizes the Src carboxy terminal negative regulatory tyrosine 530. Oncogene 1999, 18:1227-1237.
85. Lutz M.P., Esser I.B., Flossmann-Kast B.B., Vogelmann R., Luhrs H., Friess H., et al. Overexpression and activation of the tyrosine kinase Src in human pancreatic carcinoma. Biochem. Biophys. Res. Commun. 1998, 243:503-508.
86. Irby R.B., Mao W., Coppola D., Kang J., Loubeau J.M., Trudeau W., et al. Activating SRC mutation in a subset of advanced human colon cancers. Nat. Genet. 1999, 21:187-190.
87. Masaki T., Okada M., Tokuda M., Shiratori Y., Hatase O., Shirai M., et al. Reduced C-terminal Src kinase (Csk) activities in hepatocellular carcinoma. Hepatology 1999, 29:379-384.
88. Palomero T., Couronne L., Khiabanian H., Kim M.Y., Ambesi-Impiombato A., Perez-Garcia A., et al. Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas. Nat. Genet. 2014, 46:166-170.
89. Schwarz L.J., Fox E.M., Balko J.M., Garrett J.T., Kuba M.G., Estrada M.V., et al. LYN-activating mutations mediate antiestrogen resistance in estrogen receptor-positive breast cancer. J. Clin. Invest. 2014, 124:5490-5502.
90. Dalgliesh G.L., Furge K., Greenman C., Chen L., Bignell G., Butler A., et al. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature 2010, 463:360-363.
91. Zang Z.J., Ong C.K., Cutcutache I., Yu W., Zhang S.L., Huang D., et al. Genetic and structural variation in the gastric cancer kinome revealed through targeted deep sequencing. Cancer Res. 2011, 71:29-39.
92. Stransky N., Egloff A.M., Tward A.D., Kostic A.D., Cibulskis K., Sivachenko A., et al. The mutational landscape of head and neck squamous cell carcinoma. Science 2011, 333:1157-1160.
93. Durinck S., Ho C., Wang N.J., Liao W., Jakkula L.R., Collisson E.A., et al. Temporal dissection of tumorigenesis in primary cancers. Cancer Discov. 2011, 1:137-143.
94. Kubo T., Kuroda Y., Kokubu A., Hosoda F., Arai Y., Hiraoka N., et al. Resequencing analysis of the human tyrosine kinase gene family in pancreatic cancer. Pancreas 2009, 38:e200-e206.
95. Tsui T., Miller W.T. Cancer-associated mutations in breast tumor kinase/PTK6 differentially affect enzyme activity and substrate recognition. Biochemistry 2015, 54:173-182.